In other reports on PODXL as a prognostic marker in colorectal [23–25, 40], pancreatic and periampullary adenocarcinoma [21, 22], using the same polyclonal antibody, the most evident prognostic cut-off was observed for membranous vs. non-membranous expression, with the former being an independent factor of poor prognosis. This evidence concerns the gene PODXL and periampullary adenocarcinoma.